Integrative Chiropractic and Functional Strategies for Hormones

Integrative Chiropractic and Functional Strategies for PCOS, SHBG, PSA, and DHEA: An Evidence-Based Guide

Abstract

In this educational post, I walk you through clinically actionable insights on sex hormone-binding globulin (SHBG), polycystic ovary syndrome (PCOS), prostate-specific antigen (PSA) interpretation, and dehydroepiandrosterone (DHEA) optimization. Drawing on recent peer-reviewed research and decades of clinical experience across functional medicine and integrative chiropractic care, I explain how hormonal transport and receptor dynamics shape symptoms, why SHBG is a powerful metabolic biomarker, how to stratify PCOS subtypes with gut-insulin axis data, and how to apply percent free PSA and annual velocity to improve prostate risk decisions. I also detail physiologic reasoning behind therapies such as GLP-1 modulation, metformin titration, spironolactone, careful testosterone dosing in insulin resistance, and targeted DHEA support. Throughout, I illustrate how integrative chiropractic frameworks—combining neuromusculoskeletal care, autonomic regulation, lifestyle strategies, and functional nutrition—enhance outcomes by normalizing neuroendocrine stress responses, improving insulin sensitivity, and reducing inflammatory load. This is a comprehensive, evidence-based roadmap designed for patients and clinicians seeking clarity and practical steps.

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In my practice, I integrate chiropractic medicine, advanced practice nursing, functional medicine, and sports therapeutics to deliver personalized, science-grounded care.

Hormone Transport and SHBG: What Clinicians and Patients Should Know

• Key concepts
  • Sex hormone-binding globulin (SHBG) is a liver-derived glycoprotein that transports and modulates the bioavailability of testosterone and estradiol in circulation (Selva et al., 2009).
  • SHBG preferentially binds androgens (testosterone and dihydrotestosterone) over estrogens, reducing the free fractions available to interact with androgen receptors in target tissues (Rosner et al., 2013).
  • Binding dynamics mean that a person can show normal total testosterone yet feel androgen-deficient when SHBG is high and free testosterone is low. Conversely, low SHBG can elevate free testosterone, increasing androgenic symptoms.
• Physiological underpinnings
  • Hepatic SHBG production is influenced by insulin, estrogen, thyroid status, and inflammatory signaling. Hyperinsulinemia suppresses SHBG transcription in hepatocytes, raising free androgen availability and contributing to metabolic dysfunction (Plymate et al., 1990; Ding et al., 2007).
  • Estrogens and thyroid hormones generally increase SHBG levels, while insulin and androgens tend to lower it (Selva et al., 2009; Rosner et al., 2013).
• Clinical implications
  • Low SHBG is a predictive marker of insulin resistance, metabolic syndrome, and cardiometabolic risk (Ding et al., 2009; Wang et al., 2013). Changes in SHBG often precede shifts in A1C, making SHBG an early signal of deteriorating glycemic control (Ding et al., 2007).
  • High SHBG is typically associated with more favorable metabolic profiles, not something we aim to suppress. The clinical task is to manage insulin resistance and tissue receptor saturation rather than arbitrarily lowering SHBG.
• Treatment rationale
  • When SHBG is high, and patients are symptomatic for low androgens, one strategy is to increase total testosterone sufficiently to saturate androgen receptors, leaving enough free testosterone to alleviate symptoms. This must be done judiciously, with close monitoring of labs and clinical response (Rosner et al., 2013).
  • Several medications and exposures increase SHBG—e.g., oral contraceptives, estrogen therapy, and alcohol—which can be leveraged or moderated depending on clinical goals (Selva et al., 2009).
• Integrative chiropractic perspective
  • Chronic sympathetic overdrive and hypothalamic-pituitary-adrenal (HPA) axis dysregulation elevate cortisol and insulin levels, which can depress SHBG and exacerbate androgenic signs. Through spinal manipulation, myofascial release, and autonomic toning (breath training, HRV-guided stress reduction), we reduce allostatic load, support insulin sensitivity, and improve hepatic signaling for healthier SHBG dynamics (Thayer & Lane, 2009; Hallman et al., 2017).
  • Combined with anti-inflammatory nutrition, sleep optimization, and progressive resistance training, chiropractic-led integrative care can normalize the neuroendocrine patterns that underpin SHBG variability.

PCOS Demystified: Insulin, Gut, and Androgen Biology

• Why PCOS is easy to miss
  • PCOS is heterogeneous: not all patients present with classic hirsutism, acne, obesity, or ovarian cysts. Some exhibit primarily irregular cycles, dysmenorrhea, or infertility, with subtle lab abnormalities (Azziz et al., 2016).
  • Diagnostic anchors include the Rotterdam criteria: any two of the following—oligo/anovulation, clinical/biochemical hyperandrogenism, and polycystic ovarian morphology—after excluding other etiologies (Rotterdam ESHRE/ASRM, 2004).
• Pathophysiology
  • Central to many PCOS phenotypes is hyperinsulinemia, reducing SHBG and increasing free testosterone, which drives acne, hirsutism, and ovulatory dysfunction (Ding et al., 2007; Azziz et al., 2016).
  • The gut microbiome modulates insulin sensitivity, intestinal permeability, and inflammatory signaling. Dysbiosis and endotoxemia amplify insulin resistance and ovarian androgen production (Qi et al., 2019).
  • Elevated LH: FSH ratio (>2:1 in some cases) reflects altered GnRH pulsatility and ovarian theca cell androgen synthesis (Franks, 2008).
• A real-world pattern I see often
  • A young, athletic woman with severe cramps and irregular cycles, minimal acne or hirsutism, yet labs show high free testosterone and elevated DHEA-S, with LH surpassing FSH. This phenotype responds to gut-directed therapy, insulin sensitization, and strategic anti-androgen support without assuming she needs overt weight loss strategies.
• Evidence-based treatments and reasoning
  • Lifestyle therapy: Anti-inflammatory nutrition, time-restricted eating, and resistance training improve insulin sensitivity and ovulation over months to years (Moran et al., 2011; Hutchison et al., 2011).
  • Metformin: Start low (e.g., 500 mg at night) and titrate toward 1,500–2,000+ mg/day as tolerated to target hepatic gluconeogenesis and peripheral insulin sensitivity; expect transient GI effects as the gut adapts (Lord et al., 2003).
  • GLP-1 receptor agonists (e.g., semaglutide): Reduce appetite, weight, and insulin levels; growing evidence shows improvements in reproductive and metabolic parameters in PCOS (Blair, 2022; Niazi et al., 2024).
  • Spironolactone: Blocks androgen receptors and inhibits 5α-reductase activity, reducing hirsutism and acne; clinical benefit typically emerges over 6–12 months. Standard doses for hirsutism often range around 100 mg daily, with careful monitoring for potassium and blood pressure (Brown et al., 2009).
  • Contraceptives with anti-androgenic progestins (e.g., drospirenone): Increase SHBG, reduce ovarian androgen production, and stabilize cycles; useful adjuncts while addressing root causes (Azziz et al., 2016).
  • Cautious testosterone therapy in insulin-resistant women: When symptoms of androgen deficiency coexist with low SHBG, start low and titrate slowly because free levels can spike, and side effects (acne, hair changes) may increase. The mantra is start low, go slow, and watch SHBG/free T dynamics.
• Integrative chiropractic care in PCOS
  • Autonomic regulation: Reducing sympathetic drive via spinal adjustments, diaphragmatic breathing, and vagal stimulation supports insulin sensitivity and menstrual regularity by lowering cortisol and improving sleep architecture (Thayer & Lane, 2009).
  • Movement prescriptions: Periodized resistance training increases GLUT4 translocation, improves hepatic insulin sensitivity, and boosts SHBG over time; we pair this with low-impact aerobic work for sustainable energy and cycle retraining (Hutchison et al., 2011).
  • Gut-directed care: Stool testing (e.g., GI mapping) helps identify dysbiosis, SIBO patterns, and inflammation; targeted probiotics, prebiotic fibers, and polyphenols reduce endotoxemia and improve metabolic signaling (Qi et al., 2019).
  • Functional nutrition: Emphasizing omega-3s, magnesium, vitamin D, and chromium supports insulin action and lowers inflammatory tone; these align with neuromusculoskeletal improvements from chiropractic care by decreasing systemic cytokine load.

How We Interpret and Act on PSA: Percent Free PSA and Velocity

• Why percent free PSA matters
  • PSA circulates in complex and free forms. The percent free PSA (%fPSA) is inversely related to prostate cancer risk: the lower the %fPSA, the higher the probability of malignancy (Catalona et al., 1998).
  • PSA alone is specific but not highly sensitive for cancer; %fPSA improves discrimination, particularly in the 4–10 ng/mL range (Catalona et al., 1998).
• Velocity and decision-making
  • PSA velocity—the annual change in PSA—helps flag aggressive pathology. A jump of >2 points within a year is concerning and should prompt advanced imaging or urology referral (Carter et al., 2000).
• Practical thresholds we use
  • If total PSA >4 ng/mL, we add percent free PSA without delay.
  • %fPSA <10%: Higher likelihood of cancer; we expedite multiparametric 3T prostate MRI or urology biopsy referral.
  • %fPSA 10–20%: Consider prostatitis treatment if symptomatic and repeat in ~3 months; MRI clarifies inflammation vs lesion.
  • %fPSA >20%: Low likelihood; monitor and retest.
  • We also account for temporary PSA elevations from intercourse, cycling, or prostatitis; finasteride lowers total PSA ~50% but does not change %fPSA, so percent free provides a clearer risk signal during 5α-reductase therapy (Thompson et al., 2005).
• Imaging-first approach
  • In my clinics, we favor 3T multiparametric MRI before biopsy when %fPSA and velocity suggest risk. The MRI can detect lesions, grade PI-RADS, and identify acute or chronic prostatitis, minimizing unnecessary biopsies and clarifying next steps (Turkbey et al., 2019).
• Testosterone therapy and PSA
  • When PSA is normal, and BPH is stable, many guidelines support proceeding with testosterone therapy while monitoring. If PSA rises rapidly or the %fPSA is low, we hold and investigate first. This approach balances symptom relief with oncologic safety (Cui et al., 2014; Morgentaler & Traish, 2009).
• Integrative chiropractic care for men’s urologic health
  • Reducing systemic inflammation and autonomic stress via spinal care, postural correction, and breathwork can decrease pelvic floor tension and improve urinary symptoms. When coupled with weight management and anti-inflammatory nutrition, patients often achieve greater PSA stability and improved quality of life.

DHEA: Neurosteroid Science and Clinical Application

• What DHEA does
  • DHEA and DHEA-S are adrenal-derived steroids with neurosteroid actions that affect mood, cognition, sexual function, skin, vasculature, and immune modulation (Maninger et al., 2009; Wolf & Kirschbaum, 1999).
  • DHEA declines from the 20s onward, often tracking with decreased vitality and well-being; lower levels are observed in neurodegenerative and mood disorders (Maninger et al., 2009).
• Brain and receptor biology
  • DHEA interacts with GABAergic, NMDA, and sigma receptor systems, modulating neuroplasticity and resilience. It provides anti-inflammatory and endothelial benefits relevant to cardiometabolic health (Maninger et al., 2009).
  • In women, DHEA may more readily convert downstream to DHT and other androgens, which can enhance libido or, if excessive, worsen acne/hair changes—hence careful dosing (Arlt et al., 1998).
• When and how I dose DHEA
  • I first optimize thyroid and sex steroids; many patients’ DHEA levels normalize with improved sleep, nutrition, and stress management. If DHEA-S is persistently low (often in the double digits), I add compounded DHEA—commonly 5–10 mg for females and 20 mg for males—and retest at 6–8 weeks.
  • Over-the-counter DHEA quality varies; if using it, 25 mg can be a starting point with close monitoring.
  • I avoid DHEA in PCOS patients with already high DHEA-S; they rarely need more and may exacerbate androgenic symptoms.
• Clinical outcomes I see
  • Patients with adequate testosterone but low DHEA often report low libido, blunted orgasm, depressed mood, and cognitive fog. Supporting DHEA resolves a surprising share of these symptoms, reinforcing that DHEA has independent CNS receptor pathways not covered by testosterone alone (Maninger et al., 2009).
• Integrative chiropractic synergy
  • By improving sleep, autonomic tone, and inflammation, chiropractic care enhances adrenal recovery and DHEA output. Structured resistance exercise also elevates neurosteroid resilience, complementing targeted supplementation.

Comprehensive Protocols: Putting It All Together

• Assessment framework
  • Detailed history: menstrual patterns, fertility, acne/hirsutism, metabolic symptoms, pelvic pain, stress load, sleep quality.
  • Labs:
    • SHBG, total and free testosterone, estradiol, LH, FSH, DHEA-S, fasting insulin, glucose, lipids, A1C, CRP.
    • For men: total PSA, percent free PSA, PSA velocity.
    • Gut health: stool analysis for dysbiosis/inflammation when PCOS or insulin resistance is suspected.
  • Imaging: 3T multiparametric MRI for concerning PSA profiles; pelvic ultrasound in PCOS when useful.
• PCOS algorithm
  • Normalize insulin: nutrition, training, sleep; metformin uptitration; consider GLP-1 agonists in refractory cases.
  • Address gut dysbiosis: targeted probiotics, prebiotics, antimicrobials when indicated; anti-inflammatory diet.
  • Anti-androgen strategy: spironolactone for hirsutism/acne; OCPs with anti-androgenic profiles where appropriate.
  • Low-SHBG caution: If testosterone is used, start very low and titrate slowly.
  • Fertility support: expect cycles to normalize over months to years; carefully discontinue agents (e.g., OCPs) when planning pregnancy, and monitor return of ovulation.
• Men’s prostate strategy
  • If PSA >4 or velocity is significant, add percent free PSA; consider MRI before biopsy.
  • Hold testosterone when %fPSA is low or velocity high; investigate first.
  • Treat prostatitis when symptomatic; retest in ~3 months.
• DHEA plan
  • Replete only when consistently low after thyroid and sex steroid optimization.
  • Monitor for androgenic side effects; adjust dose accordingly.

Clinical Observations From My Practice

• Many insulin-resistant patients exhibit low SHBG levels months before glucose or A1C levels shift. Early lifestyle intervention prevents downstream androgenic symptoms and menstrual dysfunction.
• A subset of lean, athletic women with PCOS present predominantly with painful, irregular cycles and high free testosterone but minimal hirsutism. Gut-directed therapy and stress regulation are decisive in restoring ovulation.
• For men, percent free PSA plus velocity reduces unnecessary biopsies. MRI-first strategy frequently reveals prostatitis rather than malignancy, allowing us to treat and monitor without overshooting into invasive procedures.
• Patients with adequate testosterone but low DHEA often regain libido and mood stability with judicious DHEA, highlighting the neurosteroid gap not filled by testosterone.

How Integrative Chiropractic Care Fits In

• Neuromusculoskeletal regulation reduces sympathetic tone, lowers cortisol levels, and improves insulin sensitivity, thereby stabilizing SHBG and sex hormone balance.
• Posture and movement corrections reduce pelvic floor tension, thereby alleviating urinary and menstrual discomfort.
• Autonomic training (breathwork, HRV-guided practices) enhances sleep architecture, key for HPA axis recovery and endogenous DHEA output.
• Functional nutrition integrated with chiropractic care accelerates metabolic improvements: omega-3s, magnesium, vitamin D, fiber-rich polyphenols, and protein-forward meals support insulin action and androgen balance.

Take-Home Pearls

• Do not aim to lower SHBG indiscriminately; manage insulin resistance and consider receptor saturation strategies when appropriate.
• PCOS is a spectrum; look for LH: FSH ratios, free testosterone, DHEA-S, and gut inflammatory markers, even in lean patients.
• Use percent free PSA and PSA velocity to determine next steps; MRI often helps distinguish prostatitis from malignancy.
• DHEA is a neurosteroid with independent CNS effects; support when truly low, avoid over-replacement in PCOS.
• Integrative chiropractic care provides autonomic and inflammatory normalization, thereby amplifying outcomes across endocrine and metabolic domains.

---

References

• Catalona, W. J., et al. (1998). Use of percent free PSA to enhance specificity of PSA in the detection of prostate cancer. JAMA
• Carter, H. B., et al. (2000). Longitudinal evaluation of PSA velocity. Urology
• Ding, E. L., et al. (2007). Sex hormone–binding globulin and risk of type 2 diabetes in women and men. JAMA
• Ding, E. L., et al. (2009). SHBG concentrations and risk of metabolic syndrome. Diabetes Care
• Franks, S. (2008). Polycystic ovary syndrome. New England Journal of Medicine
• Hallman, D. M., et al. (2017). Autonomic regulation and musculoskeletal pain: A review. Scandinavian Journal of Pain
• Hutchison, S. K., et al. (2011). Exercise improves insulin resistance and body composition in PCOS. Clinical Endocrinology
• Lord, J., et al. (2003). Metformin in women with PCOS: Systematic review and meta-analysis. BMJ
• Maninger, N., et al. (2009). Neurobiological and neuropsychiatric effects of DHEA. Psychoneuroendocrinology
• Moran, L. J., et al. (2011). Lifestyle changes improve reproductive function in PCOS. Human Reproduction Update
• Morgentaler, A., & Traish, A. (2009). Shifting the paradigm of testosterone and prostate cancer: The saturation model. European Urology
• Niazi, M., et al. (2024). GLP-1 receptor agonists in PCOS: A systematic review. Frontiers in Endocrinology
• Plymate, S. R., et al. (1990). Regulation of SHBG production by insulin. Journal of Clinical Endocrinology & Metabolism
• Qi, X., et al. (2019). Gut microbiota and PCOS: Connections and interventions. Frontiers in Endocrinology
• Rosner, W., et al. (2013). Utility of free hormone measurement: SHBG dynamics and bioavailability. Journal of Clinical Endocrinology & Metabolism
• Selva, D. M., et al. (2009). Hormonal regulation of SHBG. Molecular Endocrinology
• Thayer, J. F., & Lane, R. D. (2009). Claude Bernard and the heart-brain connection: Autonomic balance and health. Neuroscience & Biobehavioral Reviews
• Thompson, I. M., et al. (2005). The effect of finasteride on PSA and prostate cancer risk. NEJM
• Turkbey, B., et al. (2019). Prostate MRI: PI-RADS v2.1 and clinical guidance. Radiology
• Wang, N., et al. (2013). SHBG and risk of metabolic syndrome in men and women. Diabetes Research and Clinical Practice
• Wolf, O. T., & Kirschbaum, C. (1999). Actions of DHEA in humans: Evidence and theory. International Journal of Neuroscience
• Blair, H. A. (2022). Semaglutide: A review in obesity and related metabolic disorders. Drugs
• Azziz, R., et al. (2016). PCOS: Pathophysiology and clinical management. Endocrine Reviews
• Cui, Y., et al. (2014). Testosterone therapy and prostate cancer risk: Meta-analysis. BJU International